MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-04-2025
BioCryst Pharmaceuticals ROA Ratio 2011-2026 | BCRX
Annual ROA Ratio BioCryst Pharmaceuticals
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -18.12 | -43.82 | -44.93 | -31.3 | -54.62 | -62.13 | -68.95 | -36.9 | -61.38 | -34.54 | -33.02 | -61.61 | -68.04 | -69.27 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -18.12 | -69.27 | -49.19 |
Quarterly ROA Ratio BioCryst Pharmaceuticals
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.15 | -4.59 | -8.39 | -13.1 | -20.01 | -24.07 | -35.6 | -31.59 | -39.2 | -39.9 | -39.75 | -35.73 | -57.86 | -58.31 | -73.89 | -60.31 | -78.38 | -70.03 | -65.99 | -54.62 | -38.04 | -45.71 | -55.64 | -62.13 | -79.31 | -78.02 | -69.12 | -68.95 | -61.24 | -49.57 | -46.48 | -36.9 | -30.95 | -35.29 | -43.94 | -61.38 | -71.18 | -70.3 | -48.18 | -35.16 | -28.86 | -23.29 | -38.0 | -33.02 | -35.6 | -45.59 | -59.8 | -61.61 | -69.75 | -70.26 | -66.72 | -68.04 | -64.84 | -65.54 | -63.96 | -69.27 | -17.59 | -19.79 | -15.85 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.15 | -79.31 | -47.71 |
ROA Ratio of other stocks in the Biotechnology industry
| Issuer | ROA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-20.13 | - | 2.43 % | $ 254 M |  Germany |
 |
ARCA biopharma
ABIO
|
-21.14 | - | 1052.0 % | $ 415 M |  USA |
 |
I-Mab
IMAB
|
7.43 | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
3.33 | - | - | $ 40.3 B | USA |
 |
Adagene
ADAG
|
-37.44 | $ 2.75 | -5.5 % | $ 155 M | China |
 |
Biophytis SA
BPTS
|
-89.6 | - | -13.47 % | $ 169 M |  France |
 |
Midatech Pharma plc
MTP
|
-42.28 | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-53.39 | - | -1.52 % | $ 24.7 M | USA |
 |
Akero Therapeutics
AKRO
|
-30.52 | - | - | $ 3.67 B | USA |
 |
Alterity Therapeutics Limited
ATHE
|
-31.06 | $ 3.17 | -2.76 % | $ 7.63 B |  Australia |
 |
PainReform Ltd.
PRFX
|
-322.39 | $ 0.68 | -4.45 % | $ 308 K |  Israel |
 |
Acorda Therapeutics
ACOR
|
-232.99 | - | -24.86 % | $ 820 K | USA |
 |
Aptose Biosciences
APTO
|
-251.11 | - | -45.71 % | $ 1.2 M |  Canada |
 |
Acasti Pharma
ACST
|
-13.29 | - | 4.01 % | $ 150 M | Canada |
 |
Aeglea BioTherapeutics
AGLE
|
-34.19 | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
-21.48 | $ 1.42 | -2.07 % | $ 266 M | USA |
 |
Albireo Pharma
ALBO
|
-11.27 | - | -0.23 % | $ 916 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
4.82 | - | - | - |  Russia |
 |
Allena Pharmaceuticals
ALNA
|
-140.01 | - | 3.16 % | $ 1.9 M | USA |
 |
Ascendis Pharma A/S
ASND
|
-35.36 | $ 225.36 | 0.63 % | $ 5 B |  Danmark |
 |
Amgen
AMGN
|
4.45 | $ 342.65 | -0.08 % | $ 184 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-150.49 | - | -11.43 % | $ 502 K | USA |
 |
Applied Molecular Transport
AMTI
|
-117.57 | - | - | $ 10.1 M | USA |
 |
ANI Pharmaceuticals
ANIP
|
-1.44 | $ 81.6 | -0.49 % | $ 1.58 B | USA |
 |
BioNTech SE
BNTX
|
65.02 | $ 114.18 | -2.22 % | $ 27.2 B | Germany |
 |
Burford Capital Limited
BUR
|
5.51 | $ 9.67 | 0.16 % | $ 1.52 B | Britain |
 |
Aravive
ARAV
|
-122.8 | - | -13.39 % | $ 1.45 M | USA |
 |
Arrowhead Pharmaceuticals
ARWR
|
-0.12 | $ 70.74 | 2.34 % | $ 9.46 B | USA |
 |
Athira Pharma
ATHA
|
-164.92 | - | - | $ 269 M | USA |
 |
Aeterna Zentaris
AEZS
|
-10.45 | - | 5.93 % | $ 314 M | Canada |
 |
Autolus Therapeutics plc
AUTL
|
-28.19 | $ 1.38 | -3.85 % | $ 352 M | Britain |
 |
AgeX Therapeutics
AGE
|
-123.72 | - | -10.17 % | $ 12.2 K | USA |
 |
AVROBIO
AVRO
|
12.03 | - | 1083.1 % | $ 745 M | USA |
 |
Akouos
AKUS
|
-31.09 | - | 0.23 % | $ 488 M | USA |
 |
Aytu BioScience
AYTU
|
-10.92 | $ 2.63 | 1.74 % | $ 16.5 M | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
-40.29 | - | -15.15 % | $ 60.3 M | Britain |
 |
Brickell Biotech
BBI
|
-49.15 | - | -5.38 % | $ 6.06 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-86.4 | $ 4.05 | -1.22 % | $ 8.81 B | Israel |
 |
Amneal Pharmaceuticals
AMRX
|
-2.11 | $ 13.65 | -3.3 % | $ 4.22 B | USA |
 |
AIkido Pharma
AIKI
|
-31.2 | - | 1.93 % | $ 17.4 M | USA |
 |
Atreca
BCEL
|
-62.67 | - | -11.76 % | $ 5.79 M | USA |
 |
CureVac N.V.
CVAC
|
-35.55 | - | - | $ 867 M | Germany |
 |
Acer Therapeutics
ACER
|
-225.71 | - | 2.71 % | $ 14 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-20.15 | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
-49.57 | - | 4.14 % | $ 49.1 M | USA |
 |
Beam Therapeutics
BEAM
|
-34.13 | $ 27.94 | -4.61 % | $ 2.3 B | USA |
 |
BeiGene, Ltd.
BGNE
|
-10.89 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Biogen
BIIB
|
5.82 | $ 178.24 | 1.2 % | $ 26 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-489.29 | - | - | $ 7.46 M | Israel |